On Wednesday (Sept. 23), U. S. stocks closed lower on Wednesday, with technology stocks leading the way.$Zoom Video Communications Inc (ZM.US) $Against the trend, it closed up by 1.61%, with an annual increase of 63.5%. Digital service e-commerce platform$Fiverr International Ltd. (FVRR.US) $It rose for three consecutive days, with an annual increase of 468%.
Biopharmaceuticals$BeiGene, Ltd. (BGNE.US) $Wednesday closed up 2.19%, infectious disease vaccine research and development company$Vaxcyte (PCVX.US) $It rose 0.33%, setting a new high in recent days.$Blueprint Medicines Corp. (BPMC.US) $The market closed at a record high for two days in a row, with a market capitalization approaching $5 billion.
Acceleron Pharma is a clinical biopharmaceutical company specializing in the development of protein therapy for cancer and rare diseases. The company's research focuses on transforming growth factor (TGF-b). By combining its development experience, the company has established a research and development platform for clinical and preclinical protein therapy.
Although the drug sotatercept (ACE-011) developed by Acceleron has failed in the treatment of thalassemia, it can still be used in clinical trials to treat pulmonary hypertension (PAH) and achieve its goal in phase 2 trials this year. Phase 3 registration trials for PAH will begin by the end of 2020.
Red blood cell maturation agent Reblozyl (luspatercept, formerly known as ACE-536) is another drug developed by Acceleron in 2010. The drug has been approved by the FDA of the United States for two indications: (1) for adult patients with β-thalassemia who need regular red blood cell transfusion to treat anemia, and (2) for adult patients with low-risk myelodysplastic syndrome (MDS) to treat anemia. In June this year, the drug was approved for the same indication in the European Union.
Despite being dragged down by the epidemic crisis this year, Reblozyl generated $55 million in sales for the company in the second quarter.
As of September 10, a total of 9 domestic new antineoplastic drugs have been approved and put on the market in 2020. In 2020, BeiGene, Ltd. occupied two potholes with the expansion of urothelial cancer indications with zebutini and tirelizumab, which was on a par with Heng Rui.
Judging from BeiGene, Ltd. 's actions this year, the company has entered the 2.0 era of development. By the end of August, BeiGene, Ltd. had six licensed transactions (mainly license in), surpassing the whole of 2019. Take the most competitive PD-1 product. BeiGene, Ltd. 's tirelizumab went on sale in March this year, with sales of about 350 million yuan in four months. if this level can be maintained, it will exceed 1 billion by the end of the year. In addition, BeiGene, Ltd. currently has at least 5 commercial products in hand, and a number of self-research and cooperative products are expected to be approved within a year.
$JinkoSolar Holding Co Ltd (JKS.US) $
CITIC believes that JinkoSolar Holding Co Ltd's 2020Q2 performance slightly exceeded expectations, profitability maintained a high level, integrated capacity expansion accelerated, and market share is expected to accelerate; the company's earnings per ADS in 2020-2022 are expected to be 40.7 yuan per ADS, corresponding to a multiple of PE in 7-6-5, giving a target price of $40.70 and maintaining a "buy" rating.
The above are US stocks that closed at a record high within the 52-week range.
Edit / allencao